文献速递甲状腺疾病

桥本甲状腺炎患者的硒补充治疗:随机临床试验的系统综述与荟萃分析

Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
PubMed 文献 · Thyroid · 2024-02-16

该系统综述与荟萃分析纳入35项随机对照试验,评估补硒对桥本甲状腺炎患者甲状腺功能、抗体、超声表现、免疫指标、患者报告结局及不良事件的影响。结果显示,未接受甲状腺激素替代治疗者补硒可降低TSH,补硒者TPOAb和丙二醛降低,不良事件与对照组相当,总体证据确定性为中等。

要点

  • 未接受甲状腺激素替代治疗的桥本甲状腺炎患者,补硒可降低TSH(SMD -0.21)。
  • 补硒可降低TPOAb(SMD -0.96)和丙二醛(SMD -1.16),降低TPOAb的指征不依赖甲状腺激素替代治疗。
  • 补硒与对照组不良事件相当(OR 0.89),总体证据确定性为中等。

核心结论

  • 在未接受甲状腺激素替代治疗的桥本甲状腺炎患者中,补硒可有效且安全地降低TSH、TPOAb和丙二醛水平。
  • 降低TPOAb的指征不依赖甲状腺激素替代治疗。

研究设计与样本

  • 研究为随机对照试验的系统综述与荟萃分析,方案注册于PROSPERO(CRD42022308377)。
  • 系统检索MEDLINE、Embase、CINHAL、Web of Science、Google Scholar和Cochrane CENTRAL Register of Trials,检索时间从建库至2023年1月,并检索纳入研究的引文。
  • 共筛选687条记录,纳入35项独特研究;由两名独立作者审阅和编码文献。
  • 主要结局为未接受甲状腺激素替代治疗患者的TSH,其余为次要结局。
  • 采用标准化均数差(SMD)或比值比(OR)合成结果,使用Cochrane RoB 2工具评估偏倚风险,采用GRADE方法评定证据质量。

主要发现

  • 补硒降低未接受甲状腺激素替代治疗患者的TSH(SMD -0.21 [CI -0.43至-0.02];7个队列,869名参与者;I²=0%)。
  • 在接受和未接受甲状腺激素替代治疗的患者中,补硒降低TPOAb(SMD -0.96 [CI -1.36至-0.56];29个队列;2358名参与者;I²=90%)和丙二醛(SMD -1.16 [CI -2.29至-0.02];3个队列;248名参与者;I²=85%)。
  • 干预组与对照组不良事件相当(OR 0.89 [CI 0.46至1.75];16个队列;1339名参与者;I²=0%)。
  • fT4、T4、fT3、T3、TGAb、甲状腺体积、白细胞介素(IL)-2和IL-10未见显著变化。
  • 总体证据确定性为中等。

局限性

  • TPOAb分析的异质性为I²=90%,丙二醛分析的异质性为I²=85%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Hashimoto thyroiditis (HT) is the most common cause of hypothyroidism in iodine-sufficient areas. Selenium is an essential trace element required for thyroid hormone synthesis and exerts antioxidant effects. Therefore, it may be of relevance in the management of HT. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the effect of selenium supplementation on thyroid function (thyrotropin [TSH], free and total thyroxine [fT4, T4], free and total triiodothyronine [fT3, T3]), thyroid antibodies (thyroid peroxidase antibodies [TPOAb], thyroglobulin antibodies [TGAb], thyrotropin receptor antibody [TRAb]), ultrasound findings (echogenicity, thyroid volume), immune markers, patient-reported outcomes, and adverse events in HT. The study protocol was registered on PROSPERO (CRD42022308377). We systematically searched MEDLINE, Embase, CINHAL, Web of Science, Google Scholar, and the Cochrane CENTRAL Register of Trials from inception to January 2023 and searched citations of eligible studies. Two independent authors reviewed and coded the identified literature. The primary outcome was TSH in patients without thyroid hormone replacement therapy (THRT); the others were considered secondary outcomes. We synthesized the results as standardized mean differences (SMD) or odds ratio (OR), assessed risk of bias using the Cochrane RoB 2 tool, and rated the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results: We screened 687 records and included 35 unique studies. Our meta-analysis found that selenium supplementation decreased TSH in patients without THRT (SMD -0.21 [confidence interval, CI -0.43 to -0.02]; 7 cohorts, 869 participants; I2 = 0%). In addition, TPOAb (SMD -0.96 [CI -1.36 to -0.56]; 29 cohorts; 2358 participants; I2 = 90%) and malondialdehyde (MDA; SMD -1.16 [CI -2.29 to -0.02]; 3 cohorts; 248 participants; I2 = 85%) decreased in patients with and without THRT. Adverse effects were comparable between the intervention and control groups (OR 0.89 [CI 0.46 to 1.75]; 16 cohorts; 1339 participants; I2 = 0%). No significant changes were observed in fT4, T4, fT3, T3, TGAb, thyroid volume, interleukin (IL)-2, and IL-10. Overall, certainty of evidence was moderate. Conclusions: In people with HT without THRT, selenium was effective and safe in lowering TSH, TPOAb, and MDA levels. Indications for lowering TPOAb were found independent of THRT.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Huwiler VV, Maissen-Abgottspon S, Stanga Z, et al. Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Thyroid. 2024. PMID: 38243784. doi:10.1089/thy.2023.0556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。